Relevant Publications
Metabolic
GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
- Auchus et al.
- 2020
J Endocr Soc. Vol 4, Issue Suppl 1 April-May
Metabolic
Reversal of Antipsychotic-Induced Weight Gain in Rats with Miricorilant, a Selective Glucocorticoid Receptor (GR) Modulator
- Lee et al.
- 2020
2020 Annual Meeting - American Psychiatric Association (APA)
Oncology
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.
- Greenstein et al.
- 2020
Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)
Metabolic
Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice
- Koorneef et al.
- 2018
- 30321321
Endocrinology. 2018, 159(12):3925–3936
Oncology
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
- Block et al.
- 2017
- 28293120
Cancer Manag Res. 2017;9:65-72.
Metabolic
The role of glucocorticoid receptors in metabolic syndrome and psychiatric illness.
- Moraitis et al.
- 2017
- 27002803
J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):114-120.
Metabolic
Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone.
- Yuen et al.
- 2017
- 29264481
J Endocr Soc. 2017;1(4):237-246.
Metabolic
Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice.
- Kroon et al.
- 2017
- 28938459
Endocrinology. 2017 Sep 18. doi:10.1210/en.2017-00512.
Other
Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective Glucocorticoid Receptor (GR) antagonist.
- Hunt et al.
- 2017
- 28368581
J Med Chem. 2017;60(8):3405-3421.
Other
Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
- Webster et al.
- 2017
- 28012176
Br J Pharmacol. 2017;174(5):396-408.